11 March 2021
Visiongain has published a new report on Alopecia Market Report to 2031: Forecasts by Disease Type (Androgenic Alopecia, Alopecia Areata, Ciatricial Alopecia, Traction Alopecia, and Alopecia Totalis), By Route of Administration (Oral, Topical, and Injectable), By Distribution Channel (Hospitals, Retail Pharmacies, and Online Pharmacies) PLUS COVID-19 Recovery Scenarios.
Global Alopecia market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.
COVID-19 Impact on Alopecia Market
COVID-19 pandemic has affected more than 200 countries worldwide. Companies have been pressured to upsurge production capacity and raise the supply of products and other commodities. The pandemic has negatively impacted all the markets and industries across the world. Visiongain has evaluated the present and possible impact of the pandemic on the global Alopecia industry, in terms of technologies employed and the materials consumed. Some market segments will be overcome however others will stay mostly unchanged. This forecast draws geographical effects with numerous distinct industries.
Rising Global Incidence of Alopecia
Changing lifestyles such as excessive consumption of alcohol and tobacco, and increasing stress indices among the population are a key factor for the growing occurrence of alopecia. However the epidemiology of the Alopecia disease is still unknown, the hereditary factor is deliberated as one of the reasons and related to numerous cases of alopecia. Also, growth in disposable income and the growing importance of aesthetics will influence the alopecia market growth in the forecasted period. As per estimates by the American Hair Loss Association, about 95% of the hair loss in males is owing to androgenic alopecia, and consciousness among people is aiding the growth of the global alopecia market.
Growing Prevalence of Stress-related Diseases
Rising incidence and prevalence of Polycystic Ovary Disease (PCOD), hypothyroidism, lupus, acute stress disorder, hypopituitarism, and multiple cancer are expected to be major driving factors for the growth of the Alopecia market during the forecast period. According to Cancer Australia estimates, around 1,405 new cases of brain cancer are expected in 2017. Also, as per the Centers for Disease Control and Prevention (CDC), nearly 1.70 million people die from a chronic disease every year in the USA. Although chronic diseases are the major reason for death for men and women alike because women face unique health issues. Around 37% of women suffer from chronic diseases, compared to 30% of men. Thereby, the rising high prevalence of Polycystic Ovary Disease (PCOD) and other chronic disorders leads to hair loss and demands proper treatment management. In turn, it is projected to attain substantial growth for the alopecia market in the given time frame.
Rapidly Increasing Health Care Expenditure
Healthcare spending has increased drastically in the U.S. in the past few decades. As per the Journal of the American Medical Association (JAMA), healthcare expenditure in the U.S. upsurge near a trillion dollars between 1996 and 2015. The association told that healthcare expenditure in the U.S. during 2017 was around $3.5 trillion, i. e, $11,000 per person. These expenditures are projected to be $6 trillion—approximately $17,000 per person by 2027.
Key players operating in the global Alopecia market are Lexington International LLC, Capillus, Johnson and Johnson Services, Inc., Vita-Cos-Med Klett-Loch GmbH, Cipla Inc., Sun Pharmaceutical Industries Ltd., Transitions Hair Pty Ltd., Merck & Co., Inc., Cirrus Hair Centers, and Follica, Inc.
The key players have adopted new product development, product launches, product approval, agreement, partnerships, and merger as its key business development strategies to tap into the global Alopecia market. For instance, on 16th March 2020, Eli Lilly and Company and Incyte Corporation publicized that the company received the U.S. Food and Drug Administration (FDA) approval for its breakthrough therapy label to baricitinib to treat against alopecia areata (AA). On the other hand, on 8th July 2020, Concert Pharmaceuticals, Inc. publicized that the company received the U.S. Food and Drug Administration (FDA) approval for its breakthrough therapy label for the company’s oral Janus kinase inhibitor, CTP-543, to treat adult patients with moderate-to-severe alopecia areata.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
19 April 2022
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
13 April 2022
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
13 April 2022
Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.